IGF-BPs controls the distribution, function and activity of IGFs in various cell tissues and body fluids. Currently there are seven named IGF-BPs that form high affinity complexes with both IGF-I and IGF-II. IGF-BP7 is expressed in a wide range of normal human tissues and it generally shows reduced expression in cancer cell lines of prostate, breast, colon, and lung origin. It plays a role in skeletal myogenesis by binding to IGF in a manner that inhibits IGF induced differentiation of skeletal myoblasts, without affecting IGF induced proliferation. Additionally, IGF-BP7 suppresses growth and colony formation of prostate and breast cancer cell lines through an IGF independent mechanism, which causes a delay in the G1 phase of the cell cycle, and increased apoptosis. Recombinant human IGF-BP7 is a 26.4kD protein consisting of 257aa.
Source:
Recombinant protein corresponding to human IGF-BP7, expressed in E.coli.
Endotoxin:
<0.1ng/ug (1EU/ug)
AA Sequence:
MSSSDTCGPC EPASCPPLPP LGCLLGETRD ACGCCPMCAR GEGEPCGGGG AGRGYCAPGM ECVKSRKRRK GKAGAAAGGP GVSGVCVCKS RYPVCGSDGT TYPSGCQLRA ASQRAESRGE KAITQVSKGT CEQGPSIVTP PKDIWNVTGA QVYLSCEVIG IPTPVLIWNK VKRGHYGVQR TELLPGDRDN LAIQTRGGPE KHEVTGWVLV SPLSKEDAGE YECHASNSQG QASASAKITV VDALHEIPVK KGEGAEL
Storage and Stability:
May be stored at 4 degrees C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
Quick Search
Products 
